National Center for Emerging and Zoonotic Infectious Diseases
National Center for Emerging and Zoonotic Infectious Diseases datasets in the CDC Open Data Catalog
This page contains all datasets in the National Center for Emerging and Zoonotic Infectious Diseases category of the CDC Open Data Catalog.
Total Datasets in Category: 6 Last Updated: 01/12/2026
Lyme disease public use aggregated data with geography, 1992-2007
Description: Overview: Public health surveillance data are collected and reported voluntarily to CDC by U.S. states and territories through the National Notifiable Diseases Surveillance System (NNDSS) (https://www.cdc.gov/nndss/index.html). Data include demographic, clinical, and geographic information; data do not include direct identifiers. Two types of datasets of human Lyme disease case data collected through public health surveillance are available: one includes annual case count aggregated by county of residence according to specific demographic variables and one is line-listed with patient demographic factors, month of illness onset, and clinical presentation information but without corresponding geographic information. These privacy-protected datasets were implemented in accordance with methodology described in Lee et al. Protecting Privacy and Transforming COVID-19 Case Surveillance Datasets for Public Use. Public Health Rep. 2021 Sep-Oct;136(5):554-561. doi: 10.1177/00333549211026817.
Lyme disease became nationally notifiable in 1991. Different surveillance case definitions have been in effect over time; details are available here: https://ndc.services.cdc.gov/conditions/lyme-disease/. In 2008, a probable case definition was included in public health surveillance for the first time. In 2022, states with a high incidence of Lyme disease started reporting cases based on laboratory evidence alone without requirement for a clinical investigation, precluding comparison with historical data (for more information: https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm?s_cid=mm7306a1_w). As such, Lyme disease surveillance data are grouped into separate datasets based on when these major changes occurred; data are provided for download separately for 1992–2007, 2008–2021, and 2022 to current. Data will be updated annually upon final verification of Lyme disease surveillance data by health departments.
Data Limitations: Surveillance data have significant limitations that must be considered in the analysis, interpretation, and reporting of results. 1. Under-reporting and misclassification are features common to all surveillance systems. Not every case of Lyme disease is reported to CDC, and some cases that are reported may be reflect illness due to another cause. 2. Please note that before the 2022 surveillance case definition went into effect, several states with high Lyme disease incidence had initiated alternative methods of surveillance and those data were not reportable to CDC. 3. Final case data are subject to each state’s abilities to capture and classify cases, which is dependent upon budget and personnel. This can vary not only between states, but also from year to year within a given state. Consequently, a sudden or marked change in reported cases does not necessarily represent a true change in disease incidence. Every effort should be made to construct analyses to limit overinterpretation of this variation (see the following reference for more context: Kugeler KJ, Eisen RJ. Challenges in Predicting Lyme Disease Risk. JAMA Netw Open. 2020 Mar 2;3(3):e200328. doi: 10.1001/jamanetworkopen.2020.0328.)
Schema: dwv_ncez_id
Table Name: lyme_disease_public_use_aggregated_data__84rx_ksgd
Dataset ID: 84rx-ksgd
Category: National Center for Emerging and Zoonotic Infectious Diseases
Total Rows: 13,180
Last Refresh: 01/01/2026
Total Batches: 1
Tags: lyme disease, surveillance
Source Data: https://data.cdc.gov/d/84rx-ksgd
Lyme disease public use aggregated data with geography, 2008-2021
Description: Overview: Public health surveillance data are collected and reported voluntarily to CDC by U.S. states and territories through the National Notifiable Diseases Surveillance System (NNDSS) (https://www.cdc.gov/nndss/index.html). Data include demographic, clinical, and geographic information; data do not include direct identifiers. Two types of datasets of human Lyme disease case data collected through public health surveillance are available: one includes annual case count aggregated by county of residence according to specific demographic variables and one is line-listed with patient demographic factors, month of illness onset, and clinical presentation information but without corresponding geographic information. These privacy-protected datasets were implemented in accordance with methodology described in Lee et al. Protecting Privacy and Transforming COVID-19 Case Surveillance Datasets for Public Use. Public Health Rep. 2021 Sep-Oct;136(5):554-561. doi: 10.1177/00333549211026817.
Lyme disease became nationally notifiable in 1991. Different surveillance case definitions have been in effect over time; details are available here: https://ndc.services.cdc.gov/conditions/lyme-disease/. In 2008, a probable case definition was included in public health surveillance for the first time. In 2022, states with a high incidence of Lyme disease started reporting cases based on laboratory evidence alone without requirement for a clinical investigation, precluding comparison with historical data (for more information: https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm?s_cid=mm7306a1_w). As such, Lyme disease surveillance data are grouped into separate datasets based on when these major changes occurred; data are provided for download separately for 1992–2007, 2008–2021, and 2022 to current. Data will be updated annually upon final verification of Lyme disease surveillance data by health departments.
Data Limitations: Surveillance data have significant limitations that must be considered in the analysis, interpretation, and reporting of results.
Under-reporting and misclassification are features common to all surveillance systems. Not every case of Lyme disease is reported to CDC, and some cases that are reported may be reflect illness due to another cause.
Please note that before the 2022 surveillance case definition went into effect, several states with high Lyme disease incidence had initiated alternative methods of surveillance and those data were not reportable to CDC.
Final case data are subject to each state’s abilities to capture and classify cases, which is dependent upon budget and personnel. This can vary not only between states, but also from year to year within a given state. Consequently, a sudden or marked change in reported cases does not necessarily represent a true change in disease incidence. Every effort should be made to construct analyses to limit overinterpretation of this variation (see the following reference for more context: Kugeler KJ, Eisen RJ. Challenges in Predicting Lyme Disease Risk. JAMA Netw Open. 2020 Mar 2;3(3):e200328. doi: 10.1001/jamanetworkopen.2020.0328.)
Schema: dwv_ncez_id
Table Name: lyme_disease_public_use_aggregated_data__qtbi_xd4i
Dataset ID: qtbi-xd4i
Category: National Center for Emerging and Zoonotic Infectious Diseases
Total Rows: 40,468
Last Refresh: 01/01/2026
Total Batches: 1
Tags: lyme disease, surveillance
Source Data: https://data.cdc.gov/d/qtbi-xd4i
Lyme disease public use aggregated data with geography, 2022-2023
Description: Overview: Public health surveillance data are collected and reported voluntarily to CDC by U.S. states and territories through the National Notifiable Diseases Surveillance System (NNDSS) (https://www.cdc.gov/nndss/index.html). Data include demographic, clinical, and geographic information; data do not include direct identifiers. Two types of datasets of human Lyme disease case data collected through public health surveillance are available: one includes annual case count aggregated by county of residence according to specific demographic variables and one is line-listed with patient demographic factors, month of illness onset, and clinical presentation information but without corresponding geographic information. These privacy-protected datasets were implemented in accordance with methodology described in Lee et al. Protecting Privacy and Transforming COVID-19 Case Surveillance Datasets for Public Use. Public Health Rep. 2021 Sep-Oct;136(5):554-561. doi: 10.1177/00333549211026817.
Lyme disease became nationally notifiable in 1991. Different surveillance case definitions have been in effect over time; details are available here: https://ndc.services.cdc.gov/conditions/lyme-disease/. In 2008, a probable case definition was included in public health surveillance for the first time. In 2022, states with a high incidence of Lyme disease started reporting cases based on laboratory evidence alone without requirement for a clinical investigation, precluding comparison with historical data (for more information: https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm?s_cid=mm7306a1_w). As such, Lyme disease surveillance data are grouped into separate datasets based on when these major changes occurred; data are provided for download separately for 1992–2007, 2008–2021, and 2022 to current. Data will be updated annually upon final verification of Lyme disease surveillance data by health departments.
Data Limitations: Surveillance data have significant limitations that must be considered in the analysis, interpretation, and reporting of results.
Under-reporting and misclassification are features common to all surveillance systems. Not every case of Lyme disease is reported to CDC, and some cases that are reported may be reflect illness due to another cause.
Please note that before the 2022 surveillance case definition went into effect, several states with high Lyme disease incidence had initiated alternative methods of surveillance and those data were not reportable to CDC.
Final case data are subject to each state’s abilities to capture and classify cases, which is dependent upon budget and personnel. This can vary not only between states, but also from year to year within a given state. Consequently, a sudden or marked change in reported cases does not necessarily represent a true change in disease incidence. Every effort should be made to construct analyses to limit overinterpretation of this variation (see the following reference for more context: Kugeler KJ, Eisen RJ. Challenges in Predicting Lyme Disease Risk. JAMA Netw Open. 2020 Mar 2;3(3):e200328. doi: 10.1001/jamanetworkopen.2020.0328.)
Schema: dwv_ncez_id
Table Name: lyme_disease_public_use_aggregated_data__x5j9_wybp
Dataset ID: x5j9-wybp
Category: National Center for Emerging and Zoonotic Infectious Diseases
Total Rows: 5,045
Last Refresh: 01/01/2026
Total Batches: 1
Tags: surveillance, lyme disease
Source Data: https://data.cdc.gov/d/x5j9-wybp
Lyme disease public use line-listed data without geography, 1992-2007
Description: Overview: Public health surveillance data are collected and reported voluntarily to CDC by U.S. states and territories through the National Notifiable Diseases Surveillance System (NNDSS) (https://www.cdc.gov/nndss/index.html). Data include demographic, clinical, and geographic information; data do not include direct identifiers. Two types of datasets of human Lyme disease case data collected through public health surveillance are available: one includes annual case count aggregated by county of residence according to specific demographic variables and one is line-listed with patient demographic factors, month of illness onset, and clinical presentation information but without corresponding geographic information. These privacy-protected datasets were implemented in accordance with methodology described in Lee et al. Protecting Privacy and Transforming COVID-19 Case Surveillance Datasets for Public Use. Public Health Rep. 2021 Sep-Oct;136(5):554-561. doi: 10.1177/00333549211026817.
Lyme disease became nationally notifiable in 1991. Different surveillance case definitions have been in effect over time; details are available here: https://ndc.services.cdc.gov/conditions/lyme-disease/. In 2008, a probable case definition was included in public health surveillance for the first time. In 2022, states with a high incidence of Lyme disease started reporting cases based on laboratory evidence alone without requirement for a clinical investigation, precluding comparison with historical data (for more information: https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm?s_cid=mm7306a1_w). As such, Lyme disease surveillance data are grouped into separate datasets based on when these major changes occurred; data are provided for download separately for 1992–2007, 2008–2021, and 2022 to current. Data will be updated annually upon final verification of Lyme disease surveillance data by health departments.
Data Limitations: Surveillance data have significant limitations that must be considered in the analysis, interpretation, and reporting of results.
Under-reporting and misclassification are features common to all surveillance systems. Not every case of Lyme disease is reported to CDC, and some cases that are reported may be reflect illness due to another cause.
Please note that before the 2022 surveillance case definition went into effect, several states with high Lyme disease incidence had initiated alternative methods of surveillance and those data were not reportable to CDC.
Final case data are subject to each state’s abilities to capture and classify cases, which is dependent upon budget and personnel. This can vary not only between states, but also from year to year within a given state. Consequently, a sudden or marked change in reported cases does not necessarily represent a true change in disease incidence. Every effort should be made to construct analyses to limit overinterpretation of this variation (see the following reference for more context: Kugeler KJ, Eisen RJ. Challenges in Predicting Lyme Disease Risk. JAMA Netw Open. 2020 Mar 2;3(3):e200328. doi: 10.1001/jamanetworkopen.2020.0328.)
Schema: dwv_ncez_id
Table Name: lyme_disease_public_use_data_1992_2007__e2a5_s9pr
Dataset ID: e2a5-s9pr
Category: National Center for Emerging and Zoonotic Infectious Diseases
Total Rows: 275,518
Last Refresh: 01/01/2026
Total Batches: 1
Tags: lyme disease, surveillance
Source Data: https://data.cdc.gov/d/e2a5-s9pr
Lyme disease public use line-listed data without geography, 2008-2021
Description: Overview: Public health surveillance data are collected and reported voluntarily to CDC by U.S. states and territories through the National Notifiable Diseases Surveillance System (NNDSS) (https://www.cdc.gov/nndss/index.html). Data include demographic, clinical, and geographic information; data do not include direct identifiers. Two types of datasets of human Lyme disease case data collected through public health surveillance are available: one includes annual case count aggregated by county of residence according to specific demographic variables and one is line-listed with patient demographic factors, month of illness onset, and clinical presentation information but without corresponding geographic information. These privacy-protected datasets were implemented in accordance with methodology described in Lee et al. Protecting Privacy and Transforming COVID-19 Case Surveillance Datasets for Public Use. Public Health Rep. 2021 Sep-Oct;136(5):554-561. doi: 10.1177/00333549211026817.
Lyme disease became nationally notifiable in 1991. Different surveillance case definitions have been in effect over time; details are available here: https://ndc.services.cdc.gov/conditions/lyme-disease/. In 2008, a probable case definition was included in public health surveillance for the first time. In 2022, states with a high incidence of Lyme disease started reporting cases based on laboratory evidence alone without requirement for a clinical investigation, precluding comparison with historical data (for more information: https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm?s_cid=mm7306a1_w). As such, Lyme disease surveillance data are grouped into separate datasets based on when these major changes occurred; data are provided for download separately for 1992–2007, 2008–2021, and 2022 to current. Data will be updated annually upon final verification of Lyme disease surveillance data by health departments.
Data Limitations: Surveillance data have significant limitations that must be considered in the analysis, interpretation, and reporting of results.
Under-reporting and misclassification are features common to all surveillance systems. Not every case of Lyme disease is reported to CDC, and some cases that are reported may be reflect illness due to another cause.
Please note that before the 2022 surveillance case definition went into effect, several states with high Lyme disease incidence had initiated alternative methods of surveillance and those data were not reportable to CDC.
Final case data are subject to each state’s abilities to capture and classify cases, which is dependent upon budget and personnel. This can vary not only between states, but also from year to year within a given state. Consequently, a sudden or marked change in reported cases does not necessarily represent a true change in disease incidence. Every effort should be made to construct analyses to limit overinterpretation of this variation (see the following reference for more context: Kugeler KJ, Eisen RJ. Challenges in Predicting Lyme Disease Risk. JAMA Netw Open. 2020 Mar 2;3(3):e200328. doi: 10.1001/jamanetworkopen.2020.0328.)
Schema: dwv_ncez_id
Table Name: lyme_disease_public_use_data_2008_to_20__abzs_b3gw
Dataset ID: abzs-b3gw
Category: National Center for Emerging and Zoonotic Infectious Diseases
Total Rows: 465,983
Last Refresh: 01/01/2026
Total Batches: 1
Tags: surveillance, lyme disease
Source Data: https://data.cdc.gov/d/abzs-b3gw
Lyme disease public use line-listed data without geography, 2022-2023
Description: Overview: Public health surveillance data are collected and reported voluntarily to CDC by U.S. states and territories through the National Notifiable Diseases Surveillance System (NNDSS) (https://www.cdc.gov/nndss/index.html). Data include demographic, clinical, and geographic information; data do not include direct identifiers. Two types of datasets of human Lyme disease case data collected through public health surveillance are available: one includes annual case count aggregated by county of residence according to specific demographic variables and one is line-listed with patient demographic factors, month of illness onset, and clinical presentation information but without corresponding geographic information. These privacy-protected datasets were implemented in accordance with methodology described in Lee et al. Protecting Privacy and Transforming COVID-19 Case Surveillance Datasets for Public Use. Public Health Rep. 2021 Sep-Oct;136(5):554-561. doi: 10.1177/00333549211026817.
Lyme disease became nationally notifiable in 1991. Different surveillance case definitions have been in effect over time; details are available here: https://ndc.services.cdc.gov/conditions/lyme-disease/. In 2008, a probable case definition was included in public health surveillance for the first time. In 2022, states with a high incidence of Lyme disease started reporting cases based on laboratory evidence alone without requirement for a clinical investigation, precluding comparison with historical data (for more information: https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm?s_cid=mm7306a1_w). As such, Lyme disease surveillance data are grouped into separate datasets based on when these major changes occurred; data are provided for download separately for 1992–2007, 2008–2021, and 2022 to current. Data will be updated annually upon final verification of Lyme disease surveillance data by health departments.
Data Limitations: Surveillance data have significant limitations that must be considered in the analysis, interpretation, and reporting of results.
Under-reporting and misclassification are features common to all surveillance systems. Not every case of Lyme disease is reported to CDC, and some cases that are reported may be reflect illness due to another cause.
Please note that before the 2022 surveillance case definition went into effect, several states with high Lyme disease incidence had initiated alternative methods of surveillance and those data were not reportable to CDC.
Final case data are subject to each state’s abilities to capture and classify cases, which is dependent upon budget and personnel. This can vary not only between states, but also from year to year within a given state. Consequently, a sudden or marked change in reported cases does not necessarily represent a true change in disease incidence. Every effort should be made to construct analyses to limit overinterpretation of this variation (see the following reference for more context: Kugeler KJ, Eisen RJ. Challenges in Predicting Lyme Disease Risk. JAMA Netw Open. 2020 Mar 2;3(3):e200328. doi: 10.1001/jamanetworkopen.2020.0328.)
Schema: dwv_ncez_id
Table Name: lyme_disease_public_use_data_no_geograp__9mtj_y2ba
Dataset ID: 9mtj-y2ba
Category: National Center for Emerging and Zoonotic Infectious Diseases
Total Rows: 152,018
Last Refresh: 01/01/2026
Total Batches: 1
Tags: lyme disease, surveillance
Source Data: https://data.cdc.gov/d/9mtj-y2ba
Last updated